Skip to main content

Page last checked

Thymic immunomodulatory peptide (approved outside the United States) · safety

Thymosin alpha-1 side effects

Also written Thymosin alpha 1.

The thymosin alpha-1 side effects reported most often are any side effect during treatment. The full list is below, with the cited trial report cited at the bottom of the page.

Rarer, but worth being able to spot: serious side effect and serious side effects attributed to the drug itself.

The sources describe these effects in relation to the dose and to the early weeks.

Thymosin alpha-1 is a peptide 28 amino acids long, first pulled out of calf thymus extract in the 1970s. It acts on how T cells mature and signal. It is sold for immune support: long COVID, chronic infection, and general resilience.

It carries a large trial record, and that record is about acutely unwell hospital patients rather than healthy adults. Under the name thymalfasin it is an approved medicine in several countries, mainly for chronic hepatitis B. Its largest trial gave it to 1,106 people with sepsis. By day 28, 23.4% had died on the drug against 24.1% on placebo.

Further down: the full list with frequencies · when to get medical help · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12open the primary sources

At a glance

Common reactions listed

1

Serious reactions listed

2

Boxed warning

No label exists

Strongest source

limited human data

The counts show how many distinct reactions the cited trial report names. The percentages show how often a reaction appeared in a study group, not the chance that it will happen to you.

Common reactions

The full list, as reported across the available trial evidence. There is no approved label to read frequency bands off, so these are the trials’ own figures.

Common reactionstrial-reported
ReactionFrequency
Any adverse event during treatment66.4% vs 67.6% on placebo (1,089 adults with sepsis, seven days of dosing)

Serious reactions to watch for

These are rarer, and they are the ones clinicians monitor for. Seek medical care if you have symptoms.

Serious — monitorwarning/precaution
ReactionFrequency
Serious adverse event26.8% vs 29.3% on placebo (same trial) — no statistically significant difference
Serious adverse events attributed to the drug itselfNone recorded in the earlier 361-participant severe-sepsis trial

limited human dataEvery reaction above comes from a cited trial. These are study findings, not instructions on what to take.

When to seek medical care

The trial report does not give a separate list of serious reactions. There is also no approved label. That gap does not mean serious reactions cannot happen. This compound has been studied in fewer people and for less time than an approved drug.

EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.

1Read deeperTiming, evidence limits, and product context

When these effects tend to occur

The cited evidence describes these effects in relation to the dose and to the early period of taking it, rather than as a constant background throughout.

When a study reports how side effects changed over time, it describes the group as a whole. It cannot predict one person’s experience.

Common questions

How long do thymosin alpha-1 side effects last, and do they go away?

The sources do not commit to a set number of days. What they describe is a pattern — reactions cluster after you start and after each increase, then ease while the dose is held steady. Any page quoting an exact number of days is quoting something the sources do not say.

What are the most common thymosin alpha-1 side effects?

Any adverse event during treatment — the table above has the rest, each with its frequency band and source.

Does thymosin alpha-1 have a boxed warning?

No, because a boxed warning is part of an FDA-approved label and thymosin alpha-1 has no approved label. That reflects what regulatory review has and has not covered, not a finding that serious risks were looked for and ruled out.

Can the thymosin alpha-1 dose be lowered if side effects are hard to tolerate?

That decision belongs to the prescribing clinician. No approved schedule exists for this compound, so there is no labeled framework for adjusting a dose. That leaves the prescriber as the only place the decision can sit.

Does thymosin alpha-1 cause hair loss?

Hair loss is not among the reactions listed on this page for thymosin alpha-1, because the cited trial report cited here does not carry it. Anything missing from the tables is outside what can be sourced here rather than ruled out, and a symptom that worries you belongs with a clinician.

Is fatigue a listed thymosin alpha-1 side effect?

No — the cited trial report cited here does not list it. That describes what was reported, not proof that the symptom cannot happen.

Is constipation a listed thymosin alpha-1 side effect?

Not separately. If a source groups stomach and gut events together, this page keeps that group intact. It does not invent named reactions the source never listed.

What should someone do about a serious thymosin alpha-1 reaction?

Contact a clinician promptly, and emergency services if symptoms are severe or getting worse quickly. The section above describes what those reactions actually look like, so they can be spotted early rather than explained away.

Do the frequencies on this page mean the chance it happens to one person?

No. These figures describe groups in a study. A band shows how often a reaction appeared under that trial’s conditions. It cannot predict what will happen to one person.

Related

The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.

Questions readers ask

Is thymosin alpha 1 safe to take?

In the largest trial unwanted events were as common on placebo: 66.4% against 67.6%, among 1,089 adults with sepsis. Serious ones ran 26.8% against 29.3%.

That is a real safety record, and it does not cover the people buying it. Everyone in these trials was acutely unwell, in hospital, under monitoring. It acts on T-cell function, which makes it a live question for anyone with autoimmune disease.

How long should you take thymosin alpha 1?

The longest published course is 52 weeks, twice a week, in a 98-patient chronic hepatitis B trial. The shortest is seven days in sepsis, one dose every 12 hours; the liver-failure trial ran 12 weeks.

Nothing published runs past a year, and nothing describes stopping and restarting. The melanoma trial is the only one that varied the quantity, across 1.6, 3.2 and 6.4 mg.

What to stack with thymosin alpha 1?

Nothing has been studied beside it, so no pairing has a safety record. The trials added it to hospital care for one illness at a time, never to another peptide.

It acts on T-cell function, and that is the reason a stack is not a neutral choice here. Anything combined with it is being combined by the person doing it.

Where to inject thymosin alpha 1?

Every registered trial gave it under the skin, and none of them compared one site with another. So there is no published best site to report.

There is no American label to name one either. What the trials do agree on is the quantity: 1.6 mg dissolved in 1 mL. Research vials sold under this name hold 5 or 10 mg.

2primary sources, each with the day we read it — open the documents used on this page